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C L I N I C A L I N Q U I R I E S
F R O M T H E F A M I L Y P R A C T I C E I N Q U I R I E S N E T W O R K
What are effective strategies for reducing 
the risk of steroid-induced osteoporosis?
EVIDENCE-BASED ANSWER Calcium, in combi-
nation with vitamin D, prevents bone loss and is
recommended in all patients. (Grade of recom-
mendation: A, based on systematic reviews of ran-
domized controlled trials [RCTs]). Alendronate and
risedronate prevent fractures and should be con-
sidered for all patients at increased risk of fracture
(5 mg of prednisone or equivalent, daily for longer
than 3 months). (Grade of recommendation: A,
based on RCTs) Replacement of sex hormones in
hypogonadal patients prevents bone loss and
increases bone mineral density (BMD). (Grade of
recommendation: A for women, based on RCTs; B
for men, based on one randomized, crossover
trial.) Calcitonin prevents bone loss for up to 1
year. (Grade of recommendation: A, based on sys-
tematic review.) 
EVIDENCE SUMMARY A systematic review of 5
RCTs (N=274) confirmed clinically and statistically
significant prevention of bone loss at the lumbar
spine for patients receiving glucocorticoids who
also received calcium (500–1000 mg daily) and
vitamin D (400–800 IU) daily.1 A systematic review
found that patients receiving steroids longer than 3
months gained bone mass when placed on a bis-
phosphonate.2 A two-year RCT of 208 patients
receiving steroids who also received alendronate
or placebo demonstrated an incidence of vertebral
fracture of 0.7% and 6.8% (NNT=16; RRR=90%;
ARR = 5.9%; P = .026), respectively.3 A 48-week
RCT involving 477 patients receiving steroids who
also received alendronate or placebo demonstrat-
ed a 2.3% and 3.7% in incidence of vertebral frac-
ture, respectively (RRR = 38%; ARR = 1.4%; P =
NS).4 A 1-year RCT of 184 men on or off steroids
using risedronate found an 82.4% decreased inci-
dence of vertebral fractures compared with those
who received placebo (NNT = 5; P = .008).5
In hypogonadal patients, several small studies
have shown that replacement of sex hormones
(estrogen in women and testosterone in men)
increases lumbar spine BMD (women 2% and
3–4%; men 5%; all P < .05). Fracture reduction and
risk of long-term use were not studied.6–8 In a sys-
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tematic review of 9 RCTs, including 441 patients,
calcitonin preserved bone mass in the lumbar
spine but not the femoral neck during the first year
of steroid therapy. Lumbar spine BMD values with
calcitonin were significantly higher than with
placebo at 6 and 12 months, but were similar at 
24 months.9
RECOMMENDATIONS FROM OTHERS The
American College of Rheumatology recommends
calcium and vitamin D be offered to all patients
initiating a regimen of prednisone 5 mg/d or its
equivalent with expected duration of longer than 3
months. Bisphosphonates should be prescribed for
all patients starting steroids and for patients receiv-
ing steroids with a T-score less than -1.0; however
they should be used with caution in pre-
menopausal women.8 A leading researcher states
the rank order for prevention is a bisphosphonate
followed by a vitamin D metabolite or hormone
replacement.10 
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